Soligenix Inc
SNGX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.38M
Close$
$1.46
202.3% upside
Current Fair Value
202.3% upsideUndervalued by 202.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.38 Million |
|---|---|
| Enterprise Value | $3.68 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.14 |
| Beta | 1.32 |
| Outstanding Shares | 10,164,898 |
Return
| Return on Equity | -270.24% |
|---|---|
| Return on Assets | -120.62% |
| Return on Invested Capital | -345.66% |
Valuation & Multiples
| P/E Ratio | -0.84 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.32 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 7, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.58%▼ 6.05% |
|---|---|
| Total Invested | $307,448▼ 48.75% |
| Investors Holding | 15▼ 2.00% |
ESG Score
No data
About Soligenix Inc
18 employees
CEO: Christopher Schaber Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.